Indian political will to be put to test as Cipla seeks Isentress voluntary licence
This article was originally published in Scrip
Executive Summary
Pressure is continuing to mount on India to demonstrate the political will to invoke compulsory licensing provisions for 'unaffordable' life-saving medicines, after another domestic firm, Cipla, said that it is seeking a voluntary licence for a cut-price version of Merck & Co's HIV drug Isentress (raltegravir).